Brief: Bone Therapeutics Sees 2021 Net Cash Burn At 16-18 Million Euros

Biosenic SA

19/01/2022 06:22

Jan 19 (Reuters) - Bone Therapeutics SA  BOTHE.BR :
    * PROVIDES FOURTH QUARTER 2021 BUSINESS UPDATE AND 2022
OUTLOOK
    * RECRUITMENT FOR ALLOB TIBIAL FACTURE PHASE IIB STUDY
ONGOING AND
ON SCHEDULE TO RELEASE TOPLINE DATA IN Q1 2023
    * DISCUSSIONS FOR ALLOB GLOBAL PARTNERSHIP STILL ONGOING
    * COMPLETION OF POTENTIAL GLOBAL PARTNERSHIP DELAYED AND NOW
ANTICIPATED IN Q1 2022
    * FINANCIAL POSITION STRENGTHENED FOLLOWING EQUITY
FUNDRAISING IN
Q4 2021 WITH RUNWAY EXPECTED INTO Q3 2022
    * NET CASH BURN FOR FULL YEAR 2021 IS ANTICIPATED TO BE EUR
16-18
MILLION
    * NET CASH POSITION TOTALED EUR 9.5 MILLION ((1)) FOR YEAR
ENDED
DECEMBER 31, 2021
    * EXPECTS TO HAVE SUFFICIENT CASH TO CARRY OUT ITS BUSINESS
OBJECTIVES INTO Q3 2022
    * 2022: WILL CONTINUE TO EXPLORE OPTIONS TO DEVELOP ITS
ALLOGENEIC
DIFFERENTIATED MSC BASED CELL THERAPY PLATFORM, BEYOND ALLOB,
INTO OTHER THERAPEUTIC INDICATIONS

Source text for Eikon:  urn:newsml:reuters.com:*:nGNE2Mjjng
Further company coverage:  BOTHE.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48587696600;))